New product: Lynparza™(olaparib) 50 mg hard capsules -

New product: Lynparza™(olaparib) 50 mg hard capsules
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cancers
Summary
Lynparza™ (olaparib) is licensed as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy.
UKMi comment
NICE is currently reviewing the clinical and cost effectiveness of olaparib within its licensed indication. Guidance is expected in September 2015.
Related links: NICE final scope for olaparib